Felix Meissner

Felix Meissner

Auto-generated profile, based on publicly available information

Felix Meissner

Institute of Innate Immunity, Department for Systems Immunology and Proteomics, Medical Faculty, University of Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cell
Verified
Journal Article
Open access
RGRoger Geiger
Roger Geiger
JRJan C. Rieckmann
Jan C. Rieckmann
TWTobias Wolf
Tobias Wolf
CBCamilla Basso
Camilla Basso
YFYuehan Feng
Yuehan Feng
ALAntonio Lanzavecchia
Antonio Lanzavecchia
Metabolic activity is intimately linked to T cell fate and function. Using high-resolution mass spectrometry, we generated dynamic metabolome and proteome profiles of human primary naive T cells following activation. We discovered critical changes in the arginine metabolism that led to a drop in intracellular L-arginine concentration. Elevating L-arginine levels induced global metabolic changes including a shift from glycolysis to oxidative phosphorylation in activated T cells and promoted the generation of central memory-like cells endowed with higher survival capacity and, in a mouse model, anti-tumor activity. Proteome-wide probing of structural alterations, validated by the analysis of knockout T cell clones, identified three transcriptional regulators (BAZ1B, PSIP1, and TSN) that sensed L-arginine levels and promoted T cell survival. Thus, intracellular L-arginine concentrations directly impact the metabolic fitness and survival capacity of T cells that are crucial for anti-tumor responses.

24 March 2021 in Nature
Verified
Journal Article
Open access
PDF file
DPDominik Pfister
Dominik Pfister
NNNicolás Gonzalo Núñez
Nicolás Gonzalo Núñez
RPRoser Pinyol
Roser Pinyol
OGOlivier Govaere
Olivier Govaere
MPMatthias Pinter
Matthias Pinter
MHMathias Heikenwälder
Mathias Heikenwälder
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

22 August 2019 in Cell
Verified
Journal Article
Closed access
SJStefan Jordan
Stefan Jordan
NTNavpreet Tung
Navpreet Tung
MCMaria Casanova-Acebes
Maria Casanova-Acebes
CCChristie Chang
Christie Chang
CCClaudia Cantoni
Claudia Cantoni
MMMiriam Merad
Miriam Merad

31 August 2015 in Nature
Verified
Journal Article
Closed access
PDF file
MWMichael Willem
Michael Willem
STSabina Tahirovic
Sabina Tahirovic
MBMarc Aurel Busche
Marc Aurel Busche
SOSaak V. Ovsepian
Saak V. Ovsepian
MCMagda Chafai
Magda Chafai
CHChristian Haass
Christian Haass

6 March 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JRJan C Rieckmann
Jan C Rieckmann
RGRoger Geiger
Roger Geiger
DHDaniel Hornburg
Daniel Hornburg
TWTobias Wolf
Tobias Wolf
KKKsenya Kveler
Ksenya Kveler
FMFelix Meissner
Felix Meissner

8 January 2016 in Science
Verified
Journal Article
Closed access
PDF file
AWAndreas C. Woerner
Andreas C. Woerner
FFFrédéric Frottin
Frédéric Frottin
DHDaniel Hornburg
Daniel Hornburg
LFLi R. Feng
Li R. Feng
FMFelix Meissner
Felix Meissner
MHMark S. Hipp
Mark S. Hipp
Location, location, location: Aggregates of certain disease-associated proteins are involved in neurodegeneration. Woerner et al. now show that the exact location of these aggregates in the cell may be the key to their pathology (see the Perspective by Da Cruz and Cleveland). An artificial aggregate-prone protein caused problems when expressed in the cytoplasm but not when expressed in the nucleus. Cytoplasmic aggregates interfered with nucleocytoplasmic import and export. Perhaps if we can shunt pathological aggregates to the nucleus in the future, we will be able to ameliorate some forms of degenerative disease. Science , this issue p. 173 ; see also p. 125